Linked Data API

Show Search Form

Search Results

1731656
registered interest false more like this
date less than 2024-10-07more like thismore than 2024-10-07
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what steps they are taking to secure funding for and expand access to minimally invasive cancer therapies approved by the National Institute for Health and Care Excellence across NHS Trusts. more like this
tabling member printed
Baroness Finlay of Llandaff remove filter
uin HL1205 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-10-11more like thismore than 2024-10-11
answer text <p>Both NHS England and integrated care boards (ICBs) are required to put in place access for any treatment that carries a positive recommendation from the Technology Appraisal programme, operated by the National Institute for Health and Care Excellence (NICE).</p><p>Where treatments are approved by NICE through the Technology Appraisals programme, the National Health Service is required to fund and make them available within agreed timescales, which vary by technology. Implementation of any NICE approvals will be supported by the service readiness assessment and the development of additional capacity where necessary.</p><p>During 2024/25, NHS England will continue to support all ICBs in integrating the planning and commissioning of suitable specialised services with their wider population-level commissioning responsibilities, in line with their individual timeline for delegation. Service Development Funding (SDF) is available to support Cancer Alliances to deliver the priorities set out in the 2024/25 NHS Operational Planning Guidance; £266 million in SDF is being provided to Cancer Alliances in 2024/25. Funding comprises two allocations: place-based, provided to all Alliances on a fair shares basis; and, targeted, provided to a selection of Alliances for agreed targeted projects. Cancer SDF is provided to Cancer Alliances via their lead ICBs to enable them to deliver on NHS-wide priorities for cancer, in line with their local delivery plans which are included in their funding agreement.</p>
answering member printed Baroness Merron more like this
question first answered
less than 2024-10-11T13:26:54.117Zmore like thismore than 2024-10-11T13:26:54.117Z
answering member
347
label Biography information for Baroness Merron more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this
1731657
registered interest false more like this
date less than 2024-10-07more like thismore than 2024-10-07
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what steps they are taking to ensure that NHS Trusts have the necessary funding and trained staff to deliver minimally invasive cancer therapies. more like this
tabling member printed
Baroness Finlay of Llandaff remove filter
uin HL1206 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-10-16more like thismore than 2024-10-16
answer text <p>The adoption of new treatments, including increasing the number and availability of minimally invasive cancer treatments, into the National Health Service in England is generally the result of National Institute for Health and Care Excellence (NICE) guidance and commissioner decisions. Both NHS England and the integrated care boards (ICBs) are required to put in place access for any treatment that carries a positive recommendation from the Technology Appraisal programme, operated by the NICE.</p><p>Where treatments are approved by the NICE through the Technology Appraisals programme, the NHS is required to fund and make them available within agreed timescales, which vary by technology. Implementation of any NICE approvals will be supported by the service readiness assessment and the development of additional capacity where necessary.</p><p>During 2024/25, NHS England will continue to support all ICBs in integrating the planning and commissioning of suitable specialised services with their wider population-level commissioning responsibilities, in line with their individual timeline for delegation.</p><p>We are committed to training the staff we need to get patients seen on time. The Government will make sure the NHS has the staff it needs to be there for all of us when we need it, including cancer patients.</p>
answering member printed Baroness Merron more like this
question first answered
less than 2024-10-16T12:07:37.82Zmore like thismore than 2024-10-16T12:07:37.82Z
answering member
347
label Biography information for Baroness Merron more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this
1726524
registered interest false more like this
date less than 2024-09-02more like thismore than 2024-09-02
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Home Care Services: Prescriptions more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what evidence they have of unrelieved symptom distress in patients when care assistants are prohibited from administering prescribed medication at home; and how many errors have been recorded when care assistants have administered prescribed breakthrough medication in the patient's home. more like this
tabling member printed
Baroness Finlay of Llandaff remove filter
uin HL596 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-09-09more like thismore than 2024-09-09
answer text <p>Good practice for homecare is set out in the National Institute for Health and Care Excellence’s (NICE) guidance, which can be found on the NICE’s website, in an online only format.</p><p>Services need to submit statutory notifications to the Care Quality Commission (CQC) when a medicines incident reaches a specific threshold. This includes an allegation of abuse, the death of a person, an incident reported to or investigated by the police, or a serious injury.</p><p>Data on anything that does not constitute the CQC threshold is not held by the CQC, but may be held by individual providers as a recorded incident.</p> more like this
answering member printed Baroness Merron more like this
question first answered
less than 2024-09-09T16:37:42.023Zmore like thismore than 2024-09-09T16:37:42.023Z
answering member
347
label Biography information for Baroness Merron more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this
1713986
registered interest false more like this
date less than 2024-04-25more like thismore than 2024-04-25
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Alcoholic Drinks: Misuse more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what assessment they have made of new data from the Office for National Statistics showing that alcohol-specific deaths are now 32.8 per cent higher than in 2019 and at an all-time high; and what steps they plan to take to tackle rising alcohol harm. more like this
tabling member printed
Baroness Finlay of Llandaff remove filter
uin HL4093 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-05-07more like thismore than 2024-05-07
answer text <p>The Government keeps all official health data related to alcohol consumption and alcohol related harms under regular review. The 2021 Public Health England publication, Monitoring alcohol consumption and harm during the COVID-19 pandemic, found that increases in alcohol consumption since the beginning of the pandemic tended to be among people who were already heavy drinkers before this period, which may be a factor in the increase.</p><p> </p><p>The most effective way to prevent alcohol specific deaths, is drinking within the United Kingdom Chief Medical Officers’ low-risk drinking guidelines, namely under 14 units per week. The Government is supporting people who drink above low-risk levels to reduce their alcohol consumption. As part of the NHS Health Check, questions are asked about alcohol consumption, and appropriate advice given to support people to make healthier choices. Those identified to be drinking at higher-risk levels are referred for liver investigation. The Department is also supporting people with alcohol dependency through the Drug Strategy and NHS Long Term Plan, by facilitating more people in need of treatment into local authority commissioned alcohol treatment services.</p>
answering member printed Lord Markham more like this
question first answered
less than 2024-05-07T12:38:31.05Zmore like thismore than 2024-05-07T12:38:31.05Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this
1713987
registered interest false more like this
date less than 2024-04-25more like thismore than 2024-04-25
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Alcoholic Drinks: Labelling more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what steps they plan to take to meet their 2020 commitment to a consultation on alcohol calorie labelling. more like this
tabling member printed
Baroness Finlay of Llandaff remove filter
uin HL4094 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-05-08more like thismore than 2024-05-08
answer text <p>The Government has previously announced an intention to consult on whether to introduce mandatory calorie labelling on alcohol. We are currently considering the evidence base, and have commissioned a National Institute for Health and Care Research study on understanding the impact of alcohol calorie labelling on alcohol and calorie selection, purchasing, and consumption.</p><p>The Government is taking a wide-ranging approach to addressing alcohol-related harms. As part of the NHS Health Check, information on alcohol consumption is provided to support people to make healthier choices. The Department continues to promote the United Kingdom’s Chief Medical Officers’ Low Risk Drinking Guidelines in England through online platforms. This provides the public with the most up-to-date scientific information, to help people make informed decisions about their own drinking, including the health harms of alcohol consumption.</p> more like this
answering member printed Lord Markham more like this
question first answered
less than 2024-05-08T15:06:15.107Zmore like thismore than 2024-05-08T15:06:15.107Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this
1701610
registered interest false more like this
date less than 2024-04-16more like thismore than 2024-04-16
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs: Prices more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what progress they have made with the proposed amendments to the Part IX of the Drug Tariff, including any impact assessments on the future provision of medical technologies in the UK; how these proposals meet the ambitions of the Life Sciences Vision; and what steps they are taking to ensure that there is sufficient patient choice following the outcome of the consultation. more like this
tabling member printed
Baroness Finlay of Llandaff remove filter
uin HL3841 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-22more like thismore than 2024-04-22
answer text <p>The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.</p><p>The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.</p><p>These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.</p><p>The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.</p>
answering member printed Lord Markham more like this
grouped question UIN HL3842 more like this
question first answered
less than 2024-04-22T15:04:52.58Zmore like thismore than 2024-04-22T15:04:52.58Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this
1701611
registered interest false more like this
date less than 2024-04-16more like thismore than 2024-04-16
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs: Prices more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government how they plan to formally engage with the wider health sector and industry partners on the next stages in the development of proposed changes to Part IX of the Drug Tariff, following the conclusion of the consultation on these proposals. more like this
tabling member printed
Baroness Finlay of Llandaff remove filter
uin HL3842 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-22more like thismore than 2024-04-22
answer text <p>The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.</p><p>The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.</p><p>These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.</p><p>The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.</p>
answering member printed Lord Markham more like this
grouped question UIN HL3841 more like this
question first answered
less than 2024-04-22T15:04:52.647Zmore like thismore than 2024-04-22T15:04:52.647Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this
1700674
registered interest false more like this
date less than 2024-04-15more like thismore than 2024-04-15
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Tofersen: Licensing more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what assessment they have made of the negative impact on pharmaceutical research investment in the UK of the refusal by National Institute for Health and Care Excellence to approve tofersen for SOD-1 MND patients in the UK. more like this
tabling member printed
Baroness Finlay of Llandaff remove filter
uin HL3732 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-22more like thismore than 2024-04-22
answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.</p> more like this
answering member printed Lord Markham more like this
grouped question UIN HL3733 more like this
question first answered
less than 2024-04-22T15:05:49.787Zmore like thismore than 2024-04-22T15:05:49.787Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this
1700675
registered interest false more like this
date less than 2024-04-15more like thismore than 2024-04-15
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Tofersen more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government what consideration was given to the costs of complicated grief in families of patients dying from SOD-1 MND during the evaluation process that led to the decision to decline access to tofersen for NHS patients. more like this
tabling member printed
Baroness Finlay of Llandaff remove filter
uin HL3733 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-22more like thismore than 2024-04-22
answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.</p> more like this
answering member printed Lord Markham more like this
grouped question UIN HL3732 more like this
question first answered
less than 2024-04-22T15:05:49.847Zmore like thismore than 2024-04-22T15:05:49.847Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this
1683932
registered interest false more like this
date less than 2024-01-22more like thismore than 2024-01-22
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Spinal Muscular Atrophy: Screening more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask His Majesty's Government when the UK National Screening Committee will publish (1) plans, and (2) timelines, for its in-service evaluation of newborn screening for spinal muscular atrophy. more like this
tabling member printed
Baroness Finlay of Llandaff remove filter
uin HL1783 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-01-30more like thismore than 2024-01-30
answer text <p>Stakeholders will be kept updated on the progress of the in-service evaluation (ISE) for newborn screening for spinal muscular atrophy (SMA) via the UK National Screening Committee’s blog, which is available in an online only format. The most recent update was published on 24 January 2024, and detailed the progress of the SMA ISE, which is available in an online only format.</p> more like this
answering member printed Lord Markham more like this
question first answered
less than 2024-01-30T11:22:13.51Zmore like thismore than 2024-01-30T11:22:13.51Z
answering member
4948
label Biography information for Lord Markham more like this
tabling member
3609
label Biography information for Baroness Finlay of Llandaff more like this